Alan F. Breier

Alan F. Breier's AcademicInfluence.com Rankings

Alan F. Breier

Biology

#7563

World Rank

#10505

Historical Rank

Neuroscience

#987

World Rank

#1028

Historical Rank

biology Degrees

Download Badge

Biology

Alan F. Breier's Degrees

Doctorate Psychiatry Stanford University

Why Is Alan F. Breier Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alan F. Breier's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. (1997) (1174)
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. (2003) (819)
The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. (1987) (787)
Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics (1997) (666)
National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. (1991) (664)
NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers (1996) (652)
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. (2000) (571)
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. (2000) (566)
The Vermont longitudinal study of persons with severe mental illness, I: Methodology, study sample, and overall status 32 years later. (1987) (563)
Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. (1984) (558)
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. (2006) (541)
Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. (1992) (504)
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. (2000) (481)
Cognitive effects of corticosteroids. (1990) (421)
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. (2002) (418)
Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. (1997) (401)
Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. (1994) (385)
Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction (2012) (375)
Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. (1999) (353)
Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. (1986) (318)
Effects of Ketamine on Thought Disorder, Working Memory, and Semantic Memory in Healthy Volunteers (1998) (301)
The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance (1994) (296)
Major depression in patients with agoraphobia and panic disorder. (1984) (295)
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. (2001) (280)
Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia. (1994) (279)
Agoraphobia with panic attacks. Development, diagnostic stability, and course of illness. (1986) (273)
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects (2005) (269)
Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. (1998) (261)
Structural abnormalities in deficit and nondeficit schizophrenia. (1993) (260)
Olanzapine versus divalproex in the treatment of acute mania. (2002) (258)
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. (2002) (257)
Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion (1997) (242)
The diagnostic validity of anxiety disorders and their relationship to depressive illness. (1985) (239)
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. (2003) (236)
A Double-Blind, Randomized Comparison of the Efficacy and Safety of Intramuscular Injections of Olanzapine, Lorazepam, or Placebo in Treating Acutely Agitated Patients Diagnosed With Bipolar Mania (2001) (235)
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis I. Study rationale and design (2003) (232)
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. (2000) (220)
Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach (1998) (220)
Self-control in psychotic disorders. (1983) (206)
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome (2003) (204)
Clozapine Blunts N-Methyl-d-Aspartate Antagonist-Induced Psychosis: A Study with Ketamine (1997) (203)
Regionally Specific Neuronal Pathology in Untreated Patients with Schizophrenia: A Proton Magnetic Resonance Spectroscopic Imaging Study (1998) (199)
Brain anatomic magnetic resonance imaging in childhood-onset schizophrenia. (1996) (198)
Kinetic Modeling of [11C]Raclopride: Combined PET-Microdialysis Studies (1997) (196)
Controllable and uncontrollable stress in humans: alterations in mood and neuroendocrine and psychophysiological function. (1987) (196)
Comparison of Rapidly Acting Intramuscular Olanzapine, Lorazepam, and Placebo: A Double-blind, Randomized Study in Acutely Agitated Patients with Dementia (2002) (194)
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis II. Baseline characteristics of the “prodromal” sample (2003) (191)
A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. (2003) (189)
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease (2004) (188)
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease (2002) (186)
Neuropsychological status of subjects at high risk for a first episode of psychosis (2004) (184)
Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. (1999) (184)
Early parental loss and development of adult psychopathology. (1988) (181)
Serotonin, schizophrenia and antipsychotic drug action (1995) (179)
Case identification and stability of the deficit syndrome of schizophrenia (1993) (172)
Characterization of schizophrenic patients who commit suicide. (1984) (172)
The Relationship between Dorsolateral Prefrontal Neuronal N-Acetylaspartate and Evoked Release of Striatal Dopamine in Schizophrenia (2000) (168)
Attentional impairments in deficit and nondeficit forms of schizophrenia. (1997) (166)
Patient response and resource management: another view of clozapine treatment of schizophrenia. (1995) (161)
Differential effect of clozapine on weight: a controlled study. (1996) (160)
Neuroleptic responsivity of negative and positive symptoms in schizophrenia. (1987) (153)
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia (2006) (146)
Temporal discounting of rewards in patients with bipolar disorder and schizophrenia. (2011) (144)
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. (2005) (140)
Dopamine D2 receptor density and personal detachment in healthy subjects. (1998) (134)
Experimental approaches to human stress research: Assessment of neurobiological mechanisms of stress in volunteers and psychiatric patients (1989) (134)
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. (2002) (133)
The role of social relationships in the recovery from psychotic disorders. (1984) (133)
A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics (1998) (132)
Borna disease virus and schizophrenia (1995) (129)
Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment. (1996) (129)
Gender differences in temporal lobe structures of patients with schizophrenia: a volumetric MRI study. (1999) (128)
Prednisone effects on neurochemistry and behavior. Preliminary findings. (1990) (124)
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. (2005) (122)
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia (2004) (121)
Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. (1996) (121)
Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. (1996) (118)
Disturbed resting state EEG synchronization in bipolar disorder: A graph-theoretic analysis☆ (2013) (118)
Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. (1993) (115)
Diazepam treatment of early signs of exacerbation in schizophrenia. (1999) (115)
The Effect of Clozapine on Plasma Norepinephrine: Relationship to Clinical Efficacy (1994) (113)
Metacognition, social cognition, and symptoms in patients with first episode and prolonged psychoses (2014) (112)
Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations. (2000) (112)
Depressive Symptoms and the Deficit Syndrome of Schizophrenia (1994) (105)
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia∗ ∗ See accompanying Editorial, in this issue. (1999) (103)
Effectiveness of antipsychotic treatment for schizophrenia: 6‐month results of the Pan‐European Schizophrenia Outpatient Health Outcomes (SOHO) study (2005) (102)
The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response (1998) (99)
Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. (1990) (94)
Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample (2000) (94)
Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study. (1994) (92)
The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes (2003) (92)
Amantadine for weight gain associated with olanzapine treatment (2004) (87)
Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study (2008) (86)
Cortical thickness across the lifespan: Data from 17,075 healthy individuals aged 3–90 years (2021) (84)
Differential effects of controllable and uncontrollable acute stress on lymphocyte proliferation and leukocyte percentages in humans (1990) (84)
Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results. (1988) (83)
Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial (2003) (83)
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. (2001) (82)
The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. (2000) (81)
Borna disease virus antibodies and the deficit syndrome of schizophrenia (1997) (80)
Clozapine response and the 5HT2C Cys23Ser polymorphism (1996) (78)
Effects of Acute Metabolic Stress on Striatal Dopamine Release in Healthy Volunteers (2000) (76)
Long‐term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia (2001) (75)
Effect of Acute Metabolic Stress on Pituitary-Adrenal Axis Activation in Patients With Schizophrenia (1998) (75)
Drug-Induced Psychosis in Parkinson Disease: Phenomenology and Correlations Among Psychosis Rating Instruments (2005) (74)
Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. (2003) (73)
The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome (1999) (72)
Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status (2002) (72)
Auditory steady state response in the schizophrenia, first-degree relatives, and schizotypal personality disorder (2012) (71)
Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures. (1992) (70)
Cognitive deficit in schizophrenia and its neurochemical basis (1999) (69)
Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population (2007) (68)
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. (2003) (66)
Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers (1988) (66)
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. (2021) (65)
5HT2a receptor T102C polymorphism and schizophrenia (1996) (65)
Seizures induced by abrupt discontinuation of alprazolam. (1984) (64)
Clinical and biochemical effects of verapamil administration to schizophrenic patients. (1987) (64)
Metacognitive Reflection and Insight Therapy for Early Psychosis: A preliminary study of a novel integrative psychotherapy (2017) (63)
Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients. (1996) (62)
The effects of metabolic stress on plasma progesterone in healthy volunteers and schizophrenic patients. (1992) (62)
Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders (2018) (62)
Verapamil concentrations in cerebrospinal fluid after oral administration. (1985) (60)
Computer-assisted cognitive remediation for schizophrenia: A randomized single-blind pilot study (2012) (59)
Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial. (2002) (58)
Greater male than female variability in regional brain structure across the lifespan (2020) (57)
Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. (1999) (57)
Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia. Relationship to prefrontal cortex volume. (1993) (57)
A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy (2015) (56)
The relation between dopamine D2 receptor density and personality: preliminary evidence from the NEO personality inventory-revised. (2000) (56)
Mechanism of Peripheral Noradrenergic Stimulation by Clozapine (1998) (56)
Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia. (1986) (55)
Effects of acute metabolic stress on plasma progesterone and testosterone in male subjects: relationship to pituitary-adrenocortical axis activation. (1997) (54)
Structural brain pathology in schizophrenia revisited. Prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid. (1987) (50)
Intramuscular Olanzapine and Intramuscular Haloperidol in Acute Schizophrenia: Antipsychotic Efficacy and Extrapyramidal Safety during the First 24 Hours of Treatment (2003) (49)
A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. (2003) (49)
Stability of neurological signs with clozapine treatment (1994) (48)
Expressed Emotion Trait or State? (1995) (48)
Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans (1992) (47)
Effects of acute metabolic stress on the dopaminergic and pituitary–adrenal axis activity in patients with schizotypal personality disorder (2004) (47)
Diabetes mellitus and antipsychotic treatment in the United Kingdom (2006) (47)
Subcortical volumes across the lifespan: Data from 18,605 healthy individuals aged 3–90 years (2021) (47)
Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. (2004) (45)
Life events in depression. Relationship to subtypes. (1985) (44)
Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. (2010) (44)
Lack of gender differences in neuroleptic response in patients with schizophrenia (1996) (42)
P02.317 Olanzapine versus risperidone: A prospective comparison of clinical and economic outcomes in schizophrenia (2000) (41)
Metacognitive Capacity as a Predictor of Insight in First-Episode Psychosis (2015) (40)
Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. (2005) (40)
A current review of olanzapine's safety in the geriatric patient: from pre‐clinical pharmacology to clinical data (2001) (39)
Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder (2008) (39)
Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis (2001) (39)
The GABAA/benzodiazepine receptor: implications for the molecular basis of anxiety. (1990) (39)
Functional neuroanatomical correlates of episodic memory impairment in early phase psychosis (2016) (38)
Plasma norepinephrine in chronic schizophrenia. (1990) (38)
Clozapine and noradrenergic function: support for a novel hypothesis for superior efficacy. (1994) (36)
Neurobiologic Correlates (1986) (36)
The effects of pharmacologic doses of 2-deoxy-d-glucose on local cerebral blood flow in the awake, unrestrained rat (1993) (36)
Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double‐blind controlled trial (2003) (35)
Current issues in the psychopharmacology of schizophrenia (2001) (35)
Schizophrenia and Other Psychoses (2008) (35)
Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. (2004) (34)
Carbamazepine maintenance treatment in outpatient schizophrenics. (1991) (33)
Developing drugs for cognitive impairment in schizophrenia. (2005) (33)
Steroid modulation of human memory: Biochemical correlates (1993) (32)
Course of Illness and Predictors of Outcome in Chronic Schizophrenia: Implications for Pathophysiology (1992) (32)
The effects of dexamethasone on plasma homovanillic acid and 3-methoxy-4-hydroxyphenylglycol. Evidence for abnormal corticosteroid-catecholamine interactions in major depression. (1987) (32)
The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease (2001) (31)
Plasma Homovanillic Acid as an Index of Central Dopaminergic Activity: Studies in Schizophrenic Patients (1988) (31)
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. (2003) (30)
The effects of pharmacological doses of 2-deoxyglucose on cerebral blood flow in healthy volunteers (1999) (29)
A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. (2009) (29)
Intravenous diazepam fails to change growth hormone and cortisol secretion in humans (1986) (28)
Prednisone decreases CSF somatostatin in healthy humans: implications for neuropsychiatric illness. (1987) (27)
Neurochemical and neural mechanisms of positive and negative symptoms in schizophrenia. (1990) (27)
Effects of Risperidone on the Peripheral Noradrenegic System in Patients with Schizophrenia: A Comparison with Clozapine and Placebo (2002) (26)
Affective systems induce formal thought disorder in early-stage psychosis. (2016) (26)
Effects of Acute Metabolic Stress on the Peripheral Vasopressinergic System in Schizophrenia (2003) (26)
Functional network connectivity in early-stage schizophrenia (2020) (25)
Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia (1993) (25)
Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: Interactions with Yohimbine (2004) (25)
Inverse relationship between plasma epinephrine and testosterone levels during acute glucoprivation in healthy men. (2001) (24)
Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: Correlations with CSF HVA (1989) (24)
Avoidance learning in schizophrenia: a dissociation between the effects of aversive and non-aversive stimuli (1999) (24)
Dissociation of benzodiazepine-induced amnesia from sedation by flumazenil pretreatment (2005) (23)
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. (2001) (23)
Apolipoprotein E ε4 and clinical phenotype in schizophrenia (1997) (23)
Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications (2004) (23)
Major depression and panic disorder: diagnostic and neurobiological relationships. (1986) (22)
Intrinsic motivation and amotivation in first episode and prolonged psychosis (2015) (22)
Cognitive effects of bilateral high frequency repetitive transcranial magnetic stimulation in early phase psychosis: a pilot study (2018) (21)
The new pharmacotherapy of schizophrenia (1996) (20)
Small sample studies: unique contributions for large sample outcome studies. (1988) (19)
Differential diagnosis and diagnostic systems in schizophrenia. (1986) (19)
Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients (1992) (18)
Internalized stigma in adults with early phase versus prolonged psychosis (2019) (18)
Mazindol Treatment of Negative Symptoms (2000) (17)
Effects of Atypical Antipsychotic Drug Treatment on Amphetamine-Induced Striatal Dopamine Release in Patients with Psychotic Disorders (1999) (16)
Characterization of white matter abnormalities in early‐stage schizophrenia (2018) (16)
D2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients. (1997) (16)
Endogenous opioid regulation of hypothalamo-pituitary-adrenal axis activity in schizophrenia (1986) (16)
Toward early estimation and treatment of addiction vulnerability: radial arm maze and N-acetyl cysteine before cocaine sensitization or nicotine self-administration in neonatal ventral hippocampal lesion rats (2016) (16)
Cortical Thickness Trajectories across the Lifespan: Data from 17,075 healthy individuals aged 3-90 years (2020) (15)
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia (1998) (15)
Olanzapine versus placebo treatment of the schizophrenia prodrome: One year results (2003) (15)
Informed consent in schizophrenia research. (1998) (14)
Specificity of plasma HVA response to dexamethasone in psychotic depression (1989) (14)
The Apolipoprotein E ε4 Allele Is Associated with Blunting of Ketamine-Induced Psychosis in Schizophrenia: A Preliminary Report (1998) (14)
Association of medial prefrontal resting state functional connectivity and metacognitive capacity in early phase psychosis (2017) (13)
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia (2000) (13)
Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study (2019) (13)
Olanzapine versus Risperidone (2000) (12)
P.2.132 A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United Kingdom (2004) (12)
Amphetamine-Induced Dopamine Release and Post-Synaptic Specific Binding in Patients with Mild Tardive Dyskinesia (2001) (12)
Subcortical Volume Trajectories across the Lifespan: Data from 18,605 healthy individuals aged 3-90 years (2020) (12)
Metabolic stress effects in normal volunteers and schizophrenic patients. (1988) (11)
Kinetic analysis of platelet monoamine oxidase in chronic schizophrenia. (1981) (11)
Allelic variation in the promoter region of the dopamine D2 receptor gene influences the antipsychotic response to clozapine (1998) (11)
Relationship of auditory electrophysiological responses to magnetic resonance spectroscopy metabolites in Early Phase Psychosis. (2019) (11)
Relationship of Metacognition and Insight to Neural Synchronization and Cognitive Function in Early Phase Psychosis (2020) (11)
Prednisone-induced behavioral and biological changes in medically healthy volunteers. (1988) (11)
A pharmacoepidemiological study of diabetes mellitus and antipsychotic treatment in the United States (2002) (11)
Metacognition in Early Phase Psychosis: Toward Understanding Neural Substrates (2015) (11)
Olanzapine in the treatment of bipolar depression (2002) (11)
Economic Outcomes Associated with Switching Individuals with Schizophrenia between Risperidone and Olanzapine (2004) (11)
Alprazolam attenuates metabolic stress-induced neuroendocrine and behavioral effects in humans (1991) (10)
Anxiogenic properties of yohimbine. II. Influence of experimental set and setting. (1992) (10)
Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia (2004) (10)
Anxiogenic properties of yohimbine (1992) (10)
Obstetric complications in schizophrenia (1991) (10)
The apolipoprotein E epsilon 4 allele is associated with blunting of ketamine-induced psychosis in schizophrenia. A preliminary report. (1998) (9)
7. Psychopathology and the question of neurodevelopmental or neurodegenerative disorder (1991) (9)
Norepinephrine and schizophrenia: a new hypothesis for antipsychotic drug action. (1998) (9)
PDB2 A RETROSPECTIVE COHORT STUDY OF DIABETES MELLITUS AND ANTIPSYCHOTIC TREATMENT IN THE UNITED KINGDOM (2002) (9)
Effects of fingolimod, a sphingosine-1-phosphate (S1P) receptor agonist, on white matter microstructure, cognition and symptoms in schizophrenia (2020) (9)
Plasma levels of catecholamines and corticotrophin during acute glucopenia induced by 2-deoxy-D-glucose in normal man (1992) (8)
A one-year double-blind comparison of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in patients with schizophrenia (2003) (8)
A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients (2000) (8)
Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a U.S. randomized controlled trial (2002) (8)
Quantitative electroencephalographic correlates of steroid administration in man. (1993) (8)
Prednisone effects on blood-brain barrier permeability and CNS IgG synthesis in healthy humans (1990) (8)
Utilization and Cost of Health Care Services During the First Episode of Psychosis. (2017) (8)
Cell type-specific manifestations of cortical thickness heterogeneity in schizophrenia (2022) (8)
The deficit syndrome: functional and structural characteristics (1991) (8)
Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone or placebo (2003) (8)
Exposure to Epstein Barr virus and cognitive functioning in individuals with schizophrenia (2021) (7)
Auditory feature perception and auditory hallucinatory experiences in schizophrenia spectrum disorder (2017) (7)
Anxiety disorders and antipsychotic drugs: a pressing need for more research. (2011) (7)
Brain morphology and schizophrenia: An MRI study of neuroanatomical circuits (1993) (7)
Superiority of olanzapine over risperidone in the control of negative symptoms of schizophrenia and related psychotic disorders in older patients (2001) (7)
Prolactin levels in olanzapine versus typical and atypical antipsychotics (1998) (7)
Novel neuroleptic dosage reduction strategies (1992) (7)
Characteristics of patients selected for treatment on a schizophrenia research unit. (1990) (7)
Seminal emission induced by tricyclic antidepressant. (1984) (7)
Failure of fusion of the septum pellucidum and the heterogeneity of schizophrenia. (1997) (7)
204. Glutamate, dopamine, the frontal cortex, and schizophrenia (1998) (6)
Is olanzapine a mood-stabilizer? (2000) (6)
Random blood glucose levels in patients with schizophrenia treated with typical and atypical antipsychotic agents: An analysis of data from double-blind, randomized, controlled clinical trial (2001) (6)
Safety of the novel antipsychotic olanzapine in the treatment of bipolar I disorder (2000) (6)
Introduction: a new era in the pharmacotherapy of psychotic disorders. (2001) (6)
Olanzapine in the treatment of mania: A placebo-controlled four-week study (1999) (6)
Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study. (2022) (5)
Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. 1993. (2000) (5)
Anxiogenic properties of yohimbine (2005) (5)
Cost-effectiveness of olanzapine compared to risperidone and haloperidol in the treatment of patients with schizophrenia: Results from a U.S. randomized controlled trial (2003) (5)
The management of treatment-resistant schizophrenia (1995) (5)
Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia. (2007) (5)
Olanzapine versus placebo for prodromal symptoms (2003) (5)
51. D2 Receptor occupancy in risperidone and clozapine-treated schizophrenics (1996) (5)
Morphometric study of prefrontal cortex and limbic structures in schizophrenia (1991) (5)
Impact of olanzapine added to lithium or valproate on the quality of life of patients with bipolar disorder (2000) (5)
Clozapine conflict [6] (1996) (5)
Metabolic stress produces rapid immunosuppression in humans. (1987) (5)
The neuroanatomy of the deficit syndrome (1992) (4)
Borna disease virus antibodies and schizophrenia (1995) (4)
Domains of psychopathology: Concept and validity (1993) (4)
Biochemical alterations produced by neuroleptics in man: studies of plasma homovanillic acid in schizophrenic patients. (1987) (4)
A comparison of olanzapine versus risperidone on improvement in negative symptoms and emotional discomfort in patients with schizophrenia (2003) (4)
Profiles of the pharmacologic response of positive and negative symptoms in schizophrenia. Comment (1987) (4)
D2 occupancy and dopamine release determined by 123I-IBZM spect following clozapine dose reduction (1995) (4)
Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer's disease (2000) (4)
The relationships of cerebellar vermis morphology to neuropsychological functions in schizophrenia and normal controls (1995) (4)
532. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer’s dementia (2000) (4)
Retrospective assessment of pre-existing diabetes progression in clinical trials of patients with serious mental illness (2003) (3)
Semantic and phonetic similarity of verbal fluency responses in early-stage psychosis (2022) (3)
Reduction of psychotic symptoms in patients with lewy body-like symptoms treated with olanzapine (2000) (3)
Hospital vs. community. (1993) (3)
Prolactin levels in olanzapine versus typical and atypical antipsychotics (1998) (3)
P.2.138 Cross-sectional comparison of fasting triglycerides in normoglycemic patients with schizophrenia treated with olanzapine, risperidone, or typical antipsychotics (2003) (3)
Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer's dementia (2000) (3)
Dr. Wolkowitz and Associates Reply (1986) (3)
Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes: response to Lean and Pajonk. (2003) (3)
Olanzapine versus haloperidol: Assessment of cognitive function in patients with schizoaffective disorder, bipolar type (1999) (3)
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type: A repeated measures analysis (1999) (3)
Depression during mania: treatment response to olanzapine or placebo (2000) (3)
Commentary: Wayne Fenton's Impact on Industry (2007) (3)
Apolipoprotein E epsilon 4 and clinical phenotype in schizophrenia. (1997) (3)
"Evaluating Acquisition Time of rfMRI in the Human Connectome Project for Early Psychosis. How Much Is Enough?" (2017) (3)
Nizatidine may ameliorate weight gain during olanzapine treatment (2001) (3)
Changes in health-related quality of life of patients with bipolar disorder treated with olanzapine (1999) (3)
Long-term outcome of DSM-III schizophrenia (1989) (2)
Long-term Outcome in Chronic Schizophrenia-Reply (1992) (2)
Prism Adaptation Deficits in Schizophrenia. (2020) (2)
Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Aizheimer's disease (1999) (2)
Clozapine treatment in schizophrenic outpatients: Preliminary results from a double-blind efficacy study (1991) (2)
Long term efficacy and safety of olanzapine in patients with inadequate initial response to haloperidol or olanzapine (1998) (2)
Clozapine conflict. (1996) (2)
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach. (2009) (2)
296. NMDA receptor function and schizophrenia: Studies with ketamine (1996) (2)
Alprazolam augmentation of neuroleptics in schizophrenia. (1989) (2)
A preliminary choroid plexus volumetric study in individuals with psychosis (2023) (2)
Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial. (2021) (2)
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RAPID-ACTING INTRAMUSCULAR OLANZAPINE AND LORAZEPAM IN ACUTELY AGITATED PATIENTS WITH DEMENTIA. (2001) (2)
199. Disrupted Integration in Early Psychosis: A Preliminary Exploration of the Relationship Between Neural Synchronization and Higher Order Cognition in a First-Episode Psychosis Sample. (2017) (2)
Efficacy and Safety of Xanomeline, a M1/M4 Receptor Preferencing Agonist, Plus Trospium, a Peripheral Muscarinic Antagonist, in Schizophrenia: Phase 2 Clinical Trial Results (2020) (2)
48. Assessment of striatal dopamine function in schizophrenia (1996) (2)
Wayne Fenton's impact on industry. (2007) (2)
P01.100 Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with alzheimer's dementia (2000) (1)
Intramuscular olanzapine: Efficacy and safety in acutely agitated patients with dementia (2001) (1)
S32. ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS POTENTIAL THERAPEUTICS FOR SCHIZOPHRENIA? (2020) (1)
T106. KARXT: A M1/M4 PREFERRING MUSCARINIC AGONIST FOR THE TREATMENT OF SCHIZOPHRENIA (2019) (1)
415. Effects of acute metabolic stress on pituitary-adrenal axis activation in patients with schizophrenia (1998) (1)
402. The Effects of 12-month, Double-Blind N-Acetyl Cysteine Treatment on Symptoms and Brain Structures in Early Phase Psychosis (2017) (1)
The multi-acting-receptor-targeted-antipsychotic (MARTA) concept of the therapeutic action of olanzapine (2000) (1)
P.2.047 Analysis of motor function in patients with Alzheimer's dementia during double-blind treatment of psychosis with olanzapine (2003) (1)
608 The NMDA receptor and schizophrenia: From phenotype to genotype (1997) (1)
Stress isn't always bad. (1988) (1)
5HT 2a receptor T102C polymorphism and schizophrenia. (1996) (1)
604 The Effects of clozapine on plasma norepinephrine kinetics in schizophrenic patients (1997) (1)
Clinical and health-related quality of life outcomes associated with olanzapine in patients with bipolar disorder as compared with haloperidol (2001) (1)
Positive and Negative Symptoms of Schizophrenia (1986) (1)
Clozapine in schizophrenic outpatients: Efficacy, longterm outcome, and relationship to prefrontal cortex (1993) (1)
P.2.082 Cognitive function in patients with Alzheimer's dementia during double-blind treatment of psychosis with olanzapine (2003) (1)
Who Commit Suicide (1984) (1)
SU-F-SPS-07: Magnetic Resonance Spectroscopy Findings in Early-Phase Psychosis. (2016) (1)
Alprazolam-neuroleptic treatment in schizophrenia (1989) (1)
Smooth and safe transition from intramuscular to oral olanzapine (2002) (1)
Non-neuroleptic treatment of prodromal symptoms (1993) (1)
The effects of treatment with antipsychotics on N-acetylaspartate measures in patients with schizophrenia (2000) (1)
Neuroanatomical localization of NMDA receptor-mediated psychosis in healthy controls and schizophrenic patients (1995) (1)
Neuropsychological status of the first-episode prodrome (2003) (1)
39. VIRUSES AND SCHIZOPHRENIA: IMPLICATIONS FOR PATHOPHYSIOLOGY AND TREATMENT (2018) (1)
278. A comparison of ketamine-induced and schizophrenic thought disorder (1998) (1)
Panic disorder: clinical features, neurobiology, and pharmacotherapy. (1991) (1)
533. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer’s disease (2000) (1)
Pharmacotherapy of First‐Episode Schizophrenia (2010) (1)
Erratum: Efficacy of olanzapine in acute bipolar maniana double-blind, placebo-controlled study (Archives of General Psychiatry (2000) 47 (841-849)) (2002) (1)
Reduction of psychotic symptoms in patients with Lewy Body-like symptoms treated with olanzapine (1999) (1)
534. Reduction of psychotic symptoms in patients with Lewy body-like symptoms treated with olanzapine (2000) (1)
Normative Modeling of Brain Morphometry Across the Lifespan Using CentileBrain: Algorithm Benchmarking and Model Optimization (2023) (0)
P490. Repetitive Transcranial Magnetic Stimulation as a Probe of Episodic Memory Neurocircuitry in Schizophrenia (2022) (0)
Predictors of outcome in schizophrenia (1989) (0)
Papers from the Symposium 'New Antipsychotic Drugs: Special Issues and Indications' 20-21 February, 1998 Marco Island, Florida. Introduction (1999) (0)
250. The dopamine hypothesis of schizophrenia—alive, well and moving ahead (1998) (0)
PSYCHOSIS IN HINDSIGHT: A COLLECTIVE RECOLLECTION OF THE ONSET OF PSYCHOSIS (2012) (0)
Gender differences in the temporal lobe, basal ganglia, and frontal lobe of patients with schizophrenia: An MRI volumetric study (1995) (0)
M182. EFFECTIVENESS OF COORDINATED SPECIALTY CARE (CSC) DELIVERED VIA TELE-HEATH COMPARED TO THE STANDARD CSC CLINIC-BASED MODEL (2020) (0)
Effects of alprazolam on metabolic stress-related alterations in HPA axis and catecholamine function in humans (1992) (0)
Glucose metabolism in deficit and non-deficit schizophrenic patients (1993) (0)
612 Predicting clozapine response: Systematic evaluation of allelic variation in candidate genes (1997) (0)
Functional neuroanatomical correlates of episodic memory impairment in early phase psychosis (2015) (0)
P.2.151 Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's dementia (2003) (0)
Borna disease virus and schizophrenia: Preliminary results (1991) (0)
Subjective Conclusions About Schizophrenia-Reply (1992) (0)
Neuroanatomical localization of ketamine-induced psychosis in schizophrenic patients and controls (1994) (0)
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia (2015) (0)
In vivo estimates of synaptic dopamine concentrations with 11C-raclopride/pet: A direct test of the dopamine hypothesis (1995) (0)
A heartfelt “thank you” to all the reviewers of Brain Imaging and Behavior in 2015 (2015) (0)
275. Is olanzapine a mood-stabilizer? (2000) (0)
Cognitive effects of bilateral high frequency repetitive transcranial magnetic stimulation in early phase psychosis: a pilot study (2018) (0)
315. Disease-Informed Assessment Identifies Robust Brain Correlates of Cognitive Performance in Psychosis and its Prodrome (2023) (0)
The Effects of Olanzapine on Cognition (2006) (0)
Innovative Therapeutics for Schizophrenia (2009) (0)
Toward early estimation and treatment of addiction vulnerability: radial arm maze and N-acetyl cysteine before cocaine sensitization or nicotine self-administration in neonatal ventral hippocampal lesion rats (2016) (0)
P.2.149 Motivational deficits: A comparison of olanzapine vs. haloperidol utilizing Bell's negative factor analysis (2003) (0)
Olanzapine versus haloperidol in transitioning from intramuscular (IM) to oral therapy (2001) (0)
SUBJECTIVE CONCLUSIONS ABOUT SCHIZOPHRENIA. AUTHOR'S REPLIES (1992) (0)
Contents of the American Journal of Psychiatry (2006) (0)
O12.3. EFFECTS OF FINGOLIMOD, A POTENT ANTI-INFLAMMATORY AGENT, ON BRAIN STRUCTURE, FUNCTION, AND SYMPTOMS IN SCHIZOPHRENIA (2019) (0)
354. The effects of metabolic and cognitive stress on cerebral blood flow (1996) (0)
Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents (2021) (0)
The effect of dosage interval on the efficacy of fluphenazine decanoate in the prevention of relapse (1993) (0)
443. Dextroamphetamine-induced neurochemical effects in chronic schizophenics and healthy volunteers (1998) (0)
News (2007) (0)
Negative symptoms and noradrenergic function (1995) (0)
494. Neuroendocrinological impacts of glucoprivic stress (1996) (0)
Subject Index Vol. 27, 1993 (1993) (0)
Effects of risperidone on catecholaminergic function in patients with schizophrenia (2000) (0)
179. Mechanism of peripheral noradrenergic stimulation by risperidone (2000) (0)
The effects of ketamine on behavioral, cognitive and neuroendocrine function in schizophrenia (1994) (0)
PMH4: CLINICAL, HUMANISTIC, AND ECONOMIC OUTCOMES ASSOCIATED WITH LONG-TERM TREATMENT OF MANIA WITH OLANZAPINE (2000) (0)
S.01.01 Are metabotropic glutamate receptors new targets for antipsychotics? (2008) (0)
240 Lack of association between 5HT2A, 5HT2C, and D4 receptor gene polymorphisms and the deficit syndrome of schizophrenia (1997) (0)
1000. High Frequency Repetitive Transcranial Magnetic Stimulation for Cognitive Impairment in Early-Phase Psychosis: A Pilot Study (2017) (0)
Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results (2023) (0)
39.4 A DOUBLE-BLIND TRIAL OF VALACYCLOVIR TO IMPROVE COGNITION IN EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE VISTA STUDY (2018) (0)
Differential actions of the new antipsychotic agents (2000) (0)
Iron and copper metabolism in children. With ramarks on schizophrenia in children. (1949) (0)
100. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia (2000) (0)
Can Quality of Life be Improved in Schizophrenia? Results From A Pragmatic, Randomized, Controlled Trial Comparing Olanzapine with First Generation Antipsychotics (2007) (0)
498 Assessment of synaptic dopamine concentrations in schizophrenia with pet (1997) (0)
Definitions of response: “Typical” and “atypical” agents in treatment-resistant and partially responsive schizophrenia (1999) (0)
Effects of metabolic stress on dopaminergic function in schizophrenia: Relationship to prefrontal cortex volume (1993) (0)
The Course of Panic Attacks and Agoraphobia-Reply (1988) (0)
Brain Activation Patterns during Visual Scene Encoding and Recognition fMRI Tasks in Early Phase Psychosis (2015) (0)
Abstracts from the ASENT 2005 Annual Meeting March 3–5, 2005 (2005) (0)
M126. Behavioral Ecological Momentary Assessment in Schizotypy and Schizophrenia: Evidence of Social Dysfunction in Daily Life (2017) (0)
Carbamazepine treatment of schizophrenia (1989) (0)
The biochemical basis for the antipsychotic effects of neuroleptics (1987) (0)
schizophrenia-spectrum disorders in a prodromal population Extracting spurious messages from noise and risk of (2012) (0)
Contents of the American Journal of Psychiatry (1993) (0)
Clozapine response and allelic variation in the 5HT2A and 5HT2C receptor genes (1996) (0)
Dissociable Cellular and Genetic Mechanisms of Cortical Thinning at Different Life Stages (2022) (0)
Clozapine treatment in patients with chronic schizophrenia: efficacy and predictors of response (1994) (0)
Retrospective assessment of risk factors for treatment emergent glucose abnormalities during randomized, double-blind clinical trials of medications for treatment of schizophrenia (2003) (0)
Metacognition in Early Phase Psychosis: Toward Understanding (2015) (0)
IS OLANZAPINE A MULTI-ACTING RECEPTOR TARGETED ANTIPSYCHOTIC (MARTA)? (2000) (0)
Retrospective analysis of risk factors in patients Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical with treatment-emergent diabetes during clinical trials of antipsychotic medications trials of antipsychotic medications (2005) (0)
Olanzapine improves apparent motivational deficits more than haloperidol in patients with schizophrenia regardless of concomitant anticholinergic medication use (2003) (0)
The role of gender in the pharmacotherapy of schizophrenia (1995) (0)
Olanzapine versus haloperidol: A prospective comparison of clinical and work status outcomes in bipolar disorder (2001) (0)
Cognitive deficits in schizophrenia (1998) (0)
Extracting spurious messages from noise Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders and risk of schizophrenia-spectrum disorders in a prodromal population in a prodromal population (2006) (0)
Notes on the reform of scientific work assessment systems in post-communist countries. (1999) (0)
P585. Frontostriatal Brain Wiring Organization in Early Psychosis Non-Affective and Early Psychosis Affective Subjects and in Healthy Controls Using a Novel Diffusion Imaging Fiber Cluster Analysis (2022) (0)
P525. Cell Type-Specific Manifestations of Cortical Thickness Heterogeneity in Schizophrenia (2022) (0)
Genetic counseling of psychotic disorders (1989) (0)
Alprazolam Augmentation of Antipsychotic Pharmacotherapy?-Reply (1989) (0)
Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer's dementia (2000) (0)
Clinical Trial of New Drug for Schizophrenia. Reply. (2021) (0)

This paper list is powered by the following services:

Alan F. Breier's Academic­Influence.com Rankings

Alan F. Breier's Degrees

Why Is Alan F. Breier Influential?

Alan F. Breier's Published Works

Published Works

Alan F. Breier's AcademicInfluence.com Rankings